Hummingbird Diagnostics GmbH (Hummingbird) is a provider of clinical research and testing services. It develops miRNA-based liquid biopsy diagnostics that find application in early detection of disease indications. The company discovers, validates, and analyzes genomic biomarkers especially derived from body fluid samples. It offers multilevel biomarker services and solutions. Hummingbird’s services comprise DNA and RNA extraction services, validation of biomarker candidates and quantitative analysis, microarray services and bioinformatic services, among others. Its products find applications in the treatment of cancer, chronic inflammatory diseases, cardiovascular diseases, and infectious disease. The company caters to pharmaceutical, biotech industry and academic life science customers. Hummingbird is headquartered in Heidelberg, Baden-Wuerttemberg, Germany.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Hummingbird Diagnostics GmbH
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Hummingbird Diagnostics GmbH Company Overview
- Hummingbird Diagnostics GmbH Company Snapshot
- Hummingbird Diagnostics GmbH Pipeline Products and Ongoing Clinical Trials Overview
- Hummingbird Diagnostics GmbH - Pipeline Analysis Overview
- Hummingbird Diagnostics GmbH - Key Facts
- Hummingbird Diagnostics GmbH - Major Products and Services
- Hummingbird Diagnostics GmbH Pipeline Products by Development Stage
- Hummingbird Diagnostics GmbH Ongoing Clinical Trials by Trial Status
- Hummingbird Diagnostics GmbH Pipeline Products Overview
- Companion Diagnostic Test - Bladder Cancer
- Companion Diagnostic Test - Bladder Cancer Product Overview
- Diagnostic Test - Acute Myocardial Infarction
- Diagnostic Test - Acute Myocardial Infarction Product Overview
- Diagnostic Test - Alzheimer's Disease
- Diagnostic Test - Alzheimer's Disease Product Overview
- Diagnostic Test - Breast Cancer
- Diagnostic Test - Breast Cancer Product Overview
- Diagnostic Test - Cancer Panel
- Diagnostic Test - Cancer Panel Product Overview
- Diagnostic Test - Heart Failure
- Diagnostic Test - Heart Failure Product Overview
- Diagnostic Test - IBD
- Diagnostic Test - IBD Product Overview
- Diagnostic Test - Melanoma
- Diagnostic Test - Melanoma Product Overview
- Diagnostic Test - Multiple Sclerosis
- Diagnostic Test - Multiple Sclerosis Product Overview
- Diagnostic Test - NSCLC
- Diagnostic Test - NSCLC Product Overview
- Diagnostic Test - Parkinson's Disease
- Diagnostic Test - Parkinson's Disease Product Overview
- miLung Blood Test
- miLung Blood Test Product Overview
- miLung Blood Test Clinical Trial
- Hummingbird Diagnostics GmbH - Key Competitors
- Hummingbird Diagnostics GmbH - Key Employees
- Hummingbird Diagnostics GmbH - Locations And Subsidiaries
- Head Office
- Recent Developments
- Hummingbird Diagnostics GmbH, Recent Developments
- Jan 23, 2024: Hummingbird Diagnostics Announces Initiation of Patient Recruitment for Clinical Study Evaluating miLungDx as a Novel Diagnostic Test for Early-stage Lung Cancer
- Oct 25, 2023: Hummingbird Diagnostics to Unveil Pioneering Alzheimer's Disease Biomarker Research at CTAD Conference
- Jul 11, 2023: Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology
- May 31, 2023: Hummingbird Diagnostics to present poster on miLung small RNA-Based Blood Test at the ASCO 2023 Annual Meeting
- Jun 23, 2022: Hummingbird Diagnostics publishes study of miRisk as a predictor of immunotherapy efficacy in advanced-stage NSCLC
- Mar 31, 2022: Hummingbird Diagnostics announces publication of study on the utility of miRisk, a blood-based microRNA analysis, to predict overall survival for advanced non-small cell lung cancer in npj Precision Oncology
- Apr 22, 2020: SkylineDx launches melanoma test in United States to support cancer care
- Dec 14, 2015: Validation of Blood-based MiRNAs for Early Diagnosis of Lung Cancer
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Hummingbird Diagnostics GmbH Pipeline Products and Ongoing Clinical Trials Overview
- Hummingbird Diagnostics GmbH Pipeline Products by Equipment Type
- Hummingbird Diagnostics GmbH Pipeline Products by Indication
- Hummingbird Diagnostics GmbH Ongoing Clinical Trials by Trial Status
- Hummingbird Diagnostics GmbH, Key Facts
- Hummingbird Diagnostics GmbH, Major Products and Services
- Hummingbird Diagnostics GmbH Number of Pipeline Products by Development Stage
- Hummingbird Diagnostics GmbH Pipeline Products Summary by Development Stage
- Hummingbird Diagnostics GmbH Ongoing Clinical Trials by Trial Status
- Hummingbird Diagnostics GmbH Ongoing Clinical Trials Summary
- Companion Diagnostic Test - Bladder Cancer - Product Status
- Companion Diagnostic Test - Bladder Cancer - Product Description
- Diagnostic Test - Acute Myocardial Infarction - Product Status
- Diagnostic Test - Acute Myocardial Infarction - Product Description
- Diagnostic Test - Alzheimer's Disease - Product Status
- Diagnostic Test - Alzheimer's Disease - Product Description
- Diagnostic Test - Breast Cancer - Product Status
- Diagnostic Test - Breast Cancer - Product Description
- Diagnostic Test - Cancer Panel - Product Status
- Diagnostic Test - Cancer Panel - Product Description
- Diagnostic Test - Heart Failure - Product Status
- Diagnostic Test - Heart Failure - Product Description
- Diagnostic Test - IBD - Product Status
- Diagnostic Test - IBD - Product Description
- Diagnostic Test - Melanoma - Product Status
- Diagnostic Test - Melanoma - Product Description
- Diagnostic Test - Multiple Sclerosis - Product Status
- Diagnostic Test - Multiple Sclerosis - Product Description
- Diagnostic Test - NSCLC - Product Status
- Diagnostic Test - NSCLC - Product Description
- Diagnostic Test - Parkinson's Disease - Product Status
- Diagnostic Test - Parkinson's Disease - Product Description
- miLung Blood Test - Product Status
- miLung Blood Test - Product Description
- miLung Blood Test - Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung "Early Detection of Lung Cancer Based on Small RNA Signatures - Boston II"
- Hummingbird Diagnostics GmbH, Key Employees
- Glossary
- Hummingbird Diagnostics GmbH Pipeline Products by Equipment Type
- Hummingbird Diagnostics GmbH Pipeline Products by Development Stage
- Hummingbird Diagnostics GmbH Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- medac GmbH
- NEO New Oncology AG
- QIAGEN GmbH
- Omega Diagnostics GmbH
- STRATIFYER Molecular Pathology GmbH
